What Are Analysts Report About Tandem Diabetes Care, Inc. (TNDM)

The analyst with the lowest target price views shares reaching $37 within the same period.

Now the shares of Tandem Diabetes Care, Inc. During its last trading session, Stock traded with the total exchanged volume of 8.57 million shares. (TNDM) are trading -88.94% downward from the 52-week high mark and 8.70% above from the fifty two-week low mark.

In company news, Tandem Diabetes Care ( TNDM ) shares fell to a record low on Thursday after the medical device company overnight priced a $22.5 million public offering of 18 million shares at $1.25 apiece, a 19% discount from Wednesday's closing price.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Tandem Diabetes Care, Inc. the EPS stands at -0.56 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.65, suggesting the stock exceeded the analysts' expectations.

According to Yahoo Finance, the price target for the company which analysts are aiming is 11.

Yesterday, the CHIEF EXECUTIVE OFFICER of Tandem Diabetes (NASDAQ: TNDM), Kim Blickenstaff, bought shares of TNDM for $2M.

Some buy side analysts are also providing their Analysis on Tandem Diabetes Care, Inc., where 2 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 4 said it's a HOLD, 1 reported it as Underperform and 0 analysts rated the stock as Sell. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.

Analyst recommendations and estimates are for informational purposes only and should be used along with a number of other factors when considering an investment position. (NASDAQ:BLUE) to report quarterly EPS of $-1.72.

For the quarter ending 11/01/2016, The Analyst projected that the company could deliver EPS of -0.58 while the company provided its Actual EPS of -0.74 showing a difference of -0.16 Percent between the Estimated and Actual EPS.

The target price for Tandem Diabetes Care, Inc.

Several analysts have released their opinion on Tandem Diabetes Care, Inc. The median estimate represents a +260.00% /span increase from the last price of 1.25.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future. (TNDM) topped its 52-week high price target of 11.3 on April 29, 2016.

The company shows its Return on Assets (ROA) value of -77.2%. The company has dropped -43.18% in past 3 months and in the last five trades has moved down -39.02%. The Stock now has a Weekly Volatility of 10.40% and Monthly Volatility of 8.09%. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0. The next year's growth is calculated to be 25.5 percent.